Vasomotor symptoms

There are 349 papers on vasomotor symptoms in aging research: 50 trials and 82 observational studies in people, 7 in animals, 188 reviews.

Disease

349 papers study it280 more mention it89 findings

52 new papers in 30 daysSee all 629 papers on vasomotor symptoms

At a glance

A human study links vasomotor symptoms with ischemic stroke in postmenopausal women; another links them with greater brain white matter hyperintensity volume in women not using hormone therapy. Reviews link severe symptoms with epigenetic age. Human trials report symptom reductions with GS1-144 in postmenopausal women and a botanical neurokinin inhibitor, whereas a saffron trial in perimenopausal women shows no clear effect.

89 findings in 62 papers from 2005 to 2026, 26 of them since April 2026

“Women who developed VMS, compared to women who did not, had significantly higher median pre-estradiol suppression trunk/limb fat mass ratios (0.8 [0.7, 0.9] vs. 0.7 [0.6, 0.7], p = 0.01)”
MON-200 An Unfavorable Cardiovascular Profile Associates With The Development Of Vasomotor Symptoms In Premenopausal Women Undergoing Experimentally Induced MenopauseENDO 2025 abstract2025doi:10.1210/jendso/bvaf149.1931
  • Human trial50
  • Humans82
  • Animals7
  • In silico3

Interventions

27

Hormone replacement therapy

downin humans10

10 studies
  1. Hormone replacement therapy decreases vasomotor symptoms in humans (eligible women after risk-reducing salpingo-oophorectomy).

    “For eligible women, menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and prevents estrogen‐deficiency bone loss.”

    Revieweligible women after risk-reducing salpingo-oophorectomyfemales

    From cancer prevention to survivorship: Comprehensive menopause management after risk‐reducing salpingo‐oophorectomy

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

  2. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).

    “Menopausal hormone therapy remains the most effective treatment for vasomotor symptoms”

    Reviewmenopause

    From Established Care to Precision Menopause Medicine: A Clinical-Actionability Framework for Contemporary Menopause Management

    Journal of clinical medicine

  3. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).

    “Hormone replacement therapy (HRT) remains the most effective treatment for vasomotor symptoms”

    Reviewmenopausefemales

    Hormone replacement therapy: an overview for South African pharmacists

    SA pharmaceutical journal.

  4. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).

    “THM is the most effective treatment for vasomotor symptoms.”

    Reviewmenopausefemales

    Management of menopausal symptoms

    FMC - Formación Médica Continuada en Atención Primaria

  5. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause) (efficacy exceeds eighty percent).

    “The results demonstrate that efficacy in controlling vasomotor symptoms exceeds eighty percent.”

    Reviewmenopausefemales

    HORMONE THERAPY IN MENOPAUSE: EVALUATION OF BENEFITS AND RISKS

    Asclepius International Journal of Scientific Health Science

  6. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).

    “MHT provides the most effective relief of vasomotor symptoms”

    Reviewmenopausefemales

    Menopausal Hormone Therapy-Risks, Benefits and Emerging Options: A Narrative Review

    International journal of molecular sciences

  7. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause) (70%-90% reduction).

    “Hormonal therapies (MHT/HRT), evolved from WHI trials, effectively reduce VMS by 70%-90%”

    Reviewmenopausefemales

    Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management

    Frontiers in reproductive health

  8. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).

    “Menopausal hormonal therapy (MHT) is supported by level 1 evidence and can address many of the negative impacts associated with menopause, including VMS.”

    Reviewmenopausefemales

    Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms

    Drugs

  9. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause transition).

    “its value in the treatment of disabling vasomotor symptoms is still undisputed.”

    Reviewmenopause transitionfemales

    Hormone therapy and cardiovascular disease: Benefits and harms

    Best practice & research. Clinical endocrinology & metabolism

  10. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).

    “Menopausal HT improves vasomotor symptoms and vulvovaginal atrophy symptoms and prevents osteoporosis-related fracture.”

    Reviewmenopausefemales

    Menopausal hormone therapy

    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC

More on Hormone replacement therapy

Elinzanetant

downin humans6downin reviews1

7 studies
  1. Elinzanetant decreases vasomotor symptoms in humans (breast cancer-related vasomotor symptoms; compared with placebo) (SMD -0.51, 95% CI -0.95 to -0.07).

    “elinzanetant (SMD -0.51, 95% CI -0.95 to -0.07)”

    Reviewbreast cancer-related vasomotor symptoms; compared with placebofemales

    Comparative efficacy and safety of nonhormonal prescription drugs for vasomotor symptoms in women with breast cancer: a systematic review and network meta-analysis

    Frontiers in pharmacology

  2. Elinzanetant decreases vasomotor symptoms in humans (moderate to severe menopausal vasomotor symptoms).

    “elinzanetant significantly reduced the frequency and severity of menopausal VMS (primary endpoints), with reductions in frequency evident as early as week 1”

    Reviewmoderate to severe menopausal vasomotor symptomsoralup to 52 weeksfemales

    Elinzanetant in moderate to severe menopausal vasomotor symptoms: a profile of its use

    Drugs & Therapy Perspectives

  3. Elinzanetant decreases vasomotor symptoms during and after menopause.

    “A neurokinin inhibitor that can alleviate vasomotor symptoms during and after menopause.”

    Reviewduring and after menopause

    Elinzanetant

    pharma-kritik

  4. Elinzanetant decreases vasomotor symptoms in humans (associated with natural/surgical menopause or endocrine therapy for breast cancer).

    “By week 12, all studies showed significant reductions vs. placebo, with benefits maintained for up to 50 weeks.”

    Reviewassociated with natural/surgical menopause or endocrine therapy for breast cancerup to 50 weeksfemales

    Consistency of efficacy and safety of elinzanetant for vasomotor symptoms and sleep disturbance associated with menopause across different populations: a review of the OASIS clinical trial program

    Maturitas

  5. Elinzanetant decreases vasomotor symptoms in menopause (65.2%-67.0% reduction).

    “elinzanetant achieved a 65.2%-67.0% reduction in VMS frequency by Week 12 (OASIS 1/2)”

    Reviewin menopauseWeek 12

    Elinzanetant: Defining the Role of Dual Neurokinin-1 and Neurokinin-3 Receptor Antagonism for Management of Vasomotor Symptoms in Menopause

    Journal of menopausal medicine

  6. Elinzanetant decreases vasomotor symptoms in humans (moderate-to-severe vasomotor symptoms associated with menopause) (MD: -2.11, 95% CrI [-3.31, -0.92]).

    “Elinzanetant significantly reduced daily VMS frequency versus PRX (MD: -2.11 [-3.31, -0.92])”

    Reviewmoderate-to-severe vasomotor symptoms associated with menopause120 mgweek 12females

    Comparative Efficacy of Elinzanetant Versus Other Non-Hormonal Pharmaceutical Therapies for the Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause: A Network Meta-Analysis

    BJOG : an international journal of obstetrics and gynaecology

  7. Elinzanetant decreases vasomotor symptoms in humans (postmenopausal women with moderate-to-severe vasomotor symptoms) (MD = -2.75, 95% CI: [-3.83, -1.67]).

    “elinzanetant demonstrated a statistically significant difference in reducing both frequency and severity of VMSs at week 4 compared to placebo (MD = -2.75, 95% CI: [-3.83, -1.67], P < 0.00001”

    Reviewpostmenopausal women with moderate-to-severe vasomotor symptomsweek 4femalesn = 1,699

    Elinzanetant: Efficacy and safety in the management of vasomotor symptoms in postmenopausal women, a systematic review and meta-analysis with grading of recommendations assessment, development, and evaluation assessment

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

More on Elinzanetant

Fezolinetant

downin humans6downin reviews1−60% vms

7 studies
  1. Fezolinetant decreases vasomotor symptoms in humans (postmenopausal women; compared with placebo) (60% to 70% reduction in VMS intensity).

    “Fezolinetant was shown to be effective and safe in reducing the frequency and severity of vasomotor symptoms (VMS) compared with placebo in postmenopausal women.”

    Reviewpostmenopausal women; compared with placebofemales

    Fezolinetant: neurokinin 3 (NK3) receptor antagonist for the treatment of menopausal vasomotor symptoms

    Universitas Médica

  2. Fezolinetant decreases vasomotor symptoms (60% decrease in VMS).

    “Non-hormonal Neurokini3 antagonists like fezolinetant, decreased VMS by 60% and benefited high-risk patients.”

    Review

    Innovative Drug Delivery Systems for Management of Menopausal Symptoms: A Systematic Review

    International journal of women's health

  3. Fezolinetant decreases vasomotor symptoms in humans (menopause) (50%-65% reduction).

    “NK3R antagonists (fezolinetant, 50%-65% VMS reduction)”

    Reviewmenopausefemales

    Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management

    Frontiers in reproductive health

  4. Fezolinetant decreases vasomotor symptoms in humans (postmenopausal women).

    “Emerging treatments like fezolinetant demonstrate promise in reducing VMS by addressing the underlying pathophysiology”

    Reviewpostmenopausal womenfemales

    Treatment of Menopausal Symptoms When Hormone Therapy Is Contraindicated

    Seminars in reproductive medicine

  5. Fezolinetant decreases vasomotor symptoms in humans (menopause).

    “Fezolinetant has shown efficacy in reducing the frequency and severity of VMS”

    Reviewmenopause

    Pharmacokinetic evaluation of fezolinetant for the treatment of vasomotor symptoms caused by menopause

    Expert opinion on drug metabolism & toxicology

  6. Fezolinetant decreases vasomotor symptoms in menopausal women.

    “NK3R antagonists provide a safe and effective treatment option for managing menopausal women with VMS.”

    Reviewin menopausal women

    Non-hormonal pharmacological interventions for managing vasomotor symptoms-how can we help: 2024 landscape

    European journal of obstetrics, gynecology, and reproductive biology

  7. Fezolinetant decreases vasomotor symptoms in humans (associated with menopause; compared with placebo).

    “Clinical trials have demonstrated fezolinetant is superior to placebo in decreasing the frequency and severity of vasomotor symptoms.”

    Reviewassociated with menopause; compared with placebo

    Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms

    The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

More on Fezolinetant

Hormone therapy

downin humans2

2 studies
  1. Hormone therapy decreases vasomotor symptoms in humans (menopause).

    “Hormone therapy remains the most effective treatment of vasomotor symptoms and genitourinary syndrome of menopause (GSM)”

    Reviewmenopause

    Hormone Therapy Considerations for Breast Cancer Survivors and High-Risk Women

    Endocrinology and metabolism clinics of North America

  2. Hormone therapy decreases vasomotor symptoms in humans (menopause).

    “Hormone therapy is the most effective treatment of vasomotor symptoms”

    Reviewmenopausefemales

    Menopause

    The Medical clinics of North America

More on Hormone therapy

Neurokinin receptor antagonists

downin humans1

1 study
  1. Neurokinin receptor antagonists decrease vasomotor symptoms in humans (menopause).

    “Neurokinin receptor antagonists, particularly fezolinetant and elinzanetant, represent the most effective evidence-based non-hormonal pharmacologic therapies currently available.”

    Reviewmenopausefemales

    Non-hormonal management of menopause symptoms—the statement of the European Society of Gynecology

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

More on Neurokinin receptor antagonists

Stellate ganglion block

downin humans1

1 study
  1. Stellate ganglion block decreases vasomotor symptoms in humans.

    “The patient underwent an ultrasound-guided supraclavicular stellate ganglion block, resulting in a favorable clinical response that was sustained for six months.”

    Human trialsevere hot flashes refractory to medical management in a patient with a history of breast cancer receiving tamoxifenultrasound-guided supraclavicularsix months

    Supraclavicular sympathetic blockade via modified stellate ganglion block for the management of persistent vasomotor symptoms in a patient with breast cancer

    Interventional pain medicine

More on Stellate ganglion block

NK3 receptor antagonists

downin humans1

1 study
  1. NK3 receptor antagonists decrease vasomotor symptoms in humans.

    “NK3 antagonists significantly and rapidly reduced VMS frequency and severity versus placebo, with sustained efficacy up to 52 weeks.”

    ReviewPerimenopausal or postmenopausal women with moderate-to-severe vasomotor symptoms; versus placeboUp to 52 weeksfemales

    EFFICACY AND SAFETY OF NON-HORMONAL NK- 3 RECEPTOR ANTAGONISTS FOR VASOMOTOR SYMPTOMS OF MENOPAUSE: A SYSTEMATIC REVIEW

    International Journal of Innovative Technologies in Social Science

More on NK3 receptor antagonists

Resistance training

downin humans1

1 study
  1. Resistance training decreases vasomotor symptoms in humans (menopausal Korean women).

    “incorporating resistance exercise into long-term exercise programs was necessary for alleviating vasomotor symptoms.”

    Reviewmenopausal Korean womenlong-termfemales

    Exercise Interventions for the Physical Management of Menopausal Korean Women: A Narrative Review of Domestic Literature

    The Asian Journal of Kinesiology

More on Resistance training

Escitalopram

downin humans1

1 study
  1. Escitalopram decreases vasomotor symptoms in humans (breast cancer-related vasomotor symptoms; compared with placebo) (SMD -1.08, 95% CI -1.80 to -0.37).

    “Five interventions were significantly more effective than placebo: escitalopram (SMD -1.08, 95% CI -1.80 to -0.37)”

    Reviewbreast cancer-related vasomotor symptoms; compared with placebofemales

    Comparative efficacy and safety of nonhormonal prescription drugs for vasomotor symptoms in women with breast cancer: a systematic review and network meta-analysis

    Frontiers in pharmacology

More on Escitalopram

Venlafaxine

downin humans1

1 study
  1. Venlafaxine decreases vasomotor symptoms in humans (breast cancer-related vasomotor symptoms; compared with placebo) (SMD -0.42, 95% CI -0.76 to -0.07).

    “venlafaxine 75 mg (SMD -0.42, 95% CI -0.76 to -0.07)”

    Reviewbreast cancer-related vasomotor symptoms; compared with placebo75 mgfemales

    Comparative efficacy and safety of nonhormonal prescription drugs for vasomotor symptoms in women with breast cancer: a systematic review and network meta-analysis

    Frontiers in pharmacology

More on Venlafaxine

Botanical neurokinin inhibitor

downin humans1

1 study
  1. Botanical neurokinin inhibitor decreases vasomotor symptoms in humans (-2.2 hot flashes per day (-47.7%) vs placebo, p = 0.003).

    “BNI supplementation reduced VMS frequency by 2.2 hot flashes per day more than placebo (p = 0.003), corresponding to a 47.7% relative decrease.”

    Human trial12 weeksn = 68

    Neurokinin pathway botanical antagonist for menopausal vasomotor symptoms: A randomized, double-blind, placebo-controlled study

    Maturitas

More on Botanical neurokinin inhibitor

GS1-144

downin humans1

1 study
  1. GS1-144 decreases vasomotor symptoms in humans (postmenopausal vasomotor symptoms) (-1.41 [-2.28 to -0.54]).

    “VMS frequency was significantly reduced versus placebo for GS1-144 30 mg BID at week 4 (difference in change in least squares mean -1.31 [90% CI: -2.35 to -0.26], P =0.04) and week 12 (-1.41 [-2.28 to -0.54], P =0.008)”

    Human trialpostmenopausal vasomotor symptoms30 mg BID12 weeksfemalesn = 276

    GS1-144 reduced hot flashes in Chinese women after menopause

    Menopause (New York, N.Y.)

More on GS1-144

Combined aerobic and resistance training

downin humans1

1 study
  1. Combined aerobic and resistance training decreases vasomotor symptoms in humans (postmenopausal women with moderate or severe VMS) (η2=0.81, p < 0.001).

    “The exercise group showed a large improvement in VMS severity (MENQOL vasomotor domain, η2=0.81, p < 0.001)”

    Human trialpostmenopausal women with moderate or severe VMS12 weeksfemalesn = 38

    Effects of exercise training on vasomotor symptoms and quality of life in postmenopausal women: a randomized controlled trial

    BMC women's health

More on Combined aerobic and resistance training

Saffron

no changein humans1

1 study
  1. Saffron showed no clear effect on vasomotor symptoms in perimenopausal women experiencing menopausal complaints.

    “However, compared to the placebo, saffron was not associated with greater improvements in vasomotor symptoms, somatic symptoms, or other quality of life measures.”

    Human trialin perimenopausal women experiencing menopausal complaintsaffron®14 mg twice daily12 weeksfemalesn = 82

    The Effects of a Saffron Extract (affron®) on Menopausal Symptoms in Women during Perimenopause: A Randomised, Double-Blind, Placebo-Controlled Study

    Journal of menopausal medicine

More on Saffron

All 27

Effects

7

Quality of life

downin humans1no changein humans1

2 studies
  1. Vasomotor symptoms were not clearly linked with quality of life in epithelial ovarian cancer survivors.

    “VMS were not associated with poor global QoL, fatigue, insomnia or mood disorders.”

    Humansin epithelial ovarian cancer survivorsfemalesn = 166

    Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study

    Gynecologic oncology

  2. Vasomotor symptoms impair quality of life in humans.

    “Severe vasomotor symptoms drive treatment seeking and can affect quality of life, mental health and work ability.”

    Review

    Risk factors, management and consequences of severe menopausal vasomotor symptoms

    Nature reviews. Endocrinology

Nitric oxide–cGMP signaling

no changein humans1

1 study
  1. Vasomotor symptoms were not clearly linked with nitric oxide–cGMP signaling in humans (assessed by NG-nitro-L-arginine methyl ester perfusion during local heating).

    “However, the NOS-mediated contribution did not differ between groups or across regions (all P > 0.15).”

    Humansassessed by NG-nitro-L-arginine methyl ester perfusion during local heatingskinfemalesn = 18

    Postmenopausal vasomotor symptoms are associated with heightened cutaneous vasodilation despite preserved nitric oxide-mediated endothelial function

    Menopause (New York, N.Y.)

More on Nitric oxide–cGMP signaling

High frequency HRV

no changein humans1

1 study
  1. Vasomotor symptoms showed no clear effect on high frequency HRV in humans (peri- and/or post-menopause) (p = 0.11).

    “There were no group differences in high frequency (HF) (p = 0.11).”

    Reviewperi- and/or post-menopause

    A systematic review of heart rate variability and menopausal vasomotor symptoms

    Physiological reports

More on High frequency HRV

Low-frequency HRV

no changein humans1

1 study
  1. Vasomotor symptoms showed no clear effect on low-frequency HRV in humans (peri- and/or post-menopause) (Difference in means: 2.715 [95% CI: -0.124 to 5.555]; p = 0.06).

    “The pooled analysis revealed no difference in low frequency (LF) in women with VMS compared to those without VMS (Difference in means: 2.715 [95% CI: -0.124 to 5.555]; p = 0.06).”

    Reviewperi- and/or post-menopause

    A systematic review of heart rate variability and menopausal vasomotor symptoms

    Physiological reports

More on Low-frequency HRV

Cardiovascular and sympathetic responsiveness to cold pressor testing

no changein humans1

1 study
  1. Vasomotor symptoms were not clearly linked with cardiovascular and sympathetic responsiveness to cold pressor testing in humans (Current or prior vasomotor symptoms compared with no history of vasomotor symptoms).

    “HR, MAP, and MSNA responsiveness to CPT were not different between groups (P > 0.05).”

    HumansCurrent or prior vasomotor symptoms compared with no history of vasomotor symptoms2-min cold pressor testfemales

    Vasomotor symptoms of menopause, sympathetic activity, and blood pressure in postmenopausal females

    American journal of physiology. Heart and circulatory physiology

Resting mean arterial pressure

no changein humans1

1 study
  1. Vasomotor symptoms were not clearly linked with resting mean arterial pressure in humans (Current or prior vasomotor symptoms compared with no history of vasomotor symptoms).

    “there were no group differences in resting mean arterial pressure (MAP) or MSNA burst frequency (P > 0.05)”

    HumansCurrent or prior vasomotor symptoms compared with no history of vasomotor symptomsfemales

    Vasomotor symptoms of menopause, sympathetic activity, and blood pressure in postmenopausal females

    American journal of physiology. Heart and circulatory physiology

More on Resting mean arterial pressure

Employment rates

no changein humans1

1 study
  1. Vasomotor symptoms were not clearly linked with employment rates in humans (menopause).

    “Vasomotor symptoms tend not to be associated with lower employment rates”

    Humansmenopausefemales

    The consequences of early menopause and menopause symptoms for labour market participation

    Social science & medicine (1982)

Upstream

1

TACR3

no changein humans1

1 study
  1. TACR3 was not clearly linked with vasomotor symptoms in humans (rare variant predicted to reduce functional NK3R levels) (P = 0.6).

    “rare variant predicted to reduce functional NK3R levels that was associated with later menarche (P = 5 × 10−9) but showed no association with VMS (P = 0.6)”

    Humansrare variant predicted to reduce functional NK3R levelsfemales

    Insights into the genetics of menopausal vasomotor symptoms: genome-wide analyses of routinely-collected primary care health records

    BMC medical genomics

More on TACR3

Associations

28

Cardiovascular disease

upin humans2

2 studies
  1. Vasomotor symptoms are associated with cardiovascular disease in humans (perimenopause).

    “vasomotor symptoms and sleep disturbance are associated with adverse cardiometabolic profiles and increased cardiovascular disease risk.”

    Reviewperimenopause

    Perimenopause and cardiometabolic risk: emerging evidence, therapeutic opportunities and unanswered questions

    Climacteric : the journal of the International Menopause Society

  2. Vasomotor symptoms are associated with cardiovascular disease in humans.

    “We review the incidence, management and potential long-term health consequences of severe vasomotor symptoms, including cardiovascular disease, diabetes mellitus, cognitive dysfunction, bone health and quality of life.”

    Review

    Risk factors, management and consequences of severe menopausal vasomotor symptoms

    Nature reviews. Endocrinology

More on Cardiovascular disease

Quality of life

downin humans2

2 studies
  1. Vasomotor symptoms are associated with quality of life in humans (Canadian perimenopausal and postmenopausal women with moderate/severe vasomotor symptoms) (Mean total Menopause-Specific Quality of Life questionnaire score: 4.3/8).

    “were associated with impairment in quality of life, work productivity, daily activities, and sleep in perimenopausal and postmenopausal women.”

    HumansCanadian perimenopausal and postmenopausal women with moderate/severe vasomotor symptomsfemalesn = 400

    Prevalence and impact of vasomotor symptoms due to menopause among women in Canada: A subgroup analysis from an international cross-sectional survey of Women with Vasomotor Symptoms Associated with Menopause (WARM Study)

    Menopause (New York, N.Y.)

  2. Vasomotor symptoms are associated with quality of life in humans (Perimenopausal and postmenopausal women with moderate to severe vasomotor symptoms).

    “showed that VMS affected quality of life across all domains measured”

    HumansPerimenopausal and postmenopausal women with moderate to severe vasomotor symptomsfemalesn = 2,176

    Prevalence and impact of vasomotor symptoms due to menopause among women in Brazil, Canada, Mexico, and Nordic Europe: a cross-sectional survey

    Menopause (New York, N.Y.)

Ischemic stroke

upin humans1OR 2.16

1 study
  1. Vasomotor symptoms predict ischemic stroke in humans (Postmenopausal women; perimenopausal and recent hot flashes) (AUC 0.809).

    “The area under the ROC curve for perimenopausal and recent hot flashes was 0.809 (p < 0.001), indicating substantial predictive value.”

    HumansPostmenopausal women; perimenopausal and recent hot flashesfemalesn = 358

    Association Between Vasomotor Symptoms and Ischemic Stroke: A Case-Control Study

    Brain and behavior

  2. Vasomotor symptoms are associated with ischemic stroke in humans (Postmenopausal women; perimenopausal vasomotor symptoms; multivariable adjustment) (OR 2.16, 95% CI 1.42–3.30).

    “both perimenopausal VMS (OR: 2.16, 95% CI: 1.42-3.30, p < 0.001) and the past week VMS (OR: 2.06, 95% CI: 1.33-3.26, p = 0.001) remained independently associated with IS.”

    HumansPostmenopausal women; perimenopausal vasomotor symptoms; multivariable adjustmentfemalesn = 358

    Association Between Vasomotor Symptoms and Ischemic Stroke: A Case-Control Study

    Brain and behavior

More on Ischemic stroke

Premenstrual disorders

upin humans1

1 study
  1. Premenstrual disorders are associated with vasomotor symptoms in humans (Age-standardized comparison with women without a history of premenstrual disorders).

    “higher prevalences of hypertension (p=0.006) and a history of VMS (p<0.001) relative to women without PMDs.”

    HumansAge-standardized comparison with women without a history of premenstrual disordersfemalesn = 4,405

    Premenstrual disorders were not linked to midlife artery disease

    ESC Congress 2026 abstract

More on Premenstrual disorders

Perinatal depression

upin humans1

1 study
  1. Perinatal depression is associated with vasomotor symptoms in humans (adjusted for age, race/ethnicity, education, parity, BMI, and smoking status) (ARR 1.14, 95% CI 1.00, 1.30).

    “Women with perinatal depression were more likely to report vasomotor symptoms (44.1%) during midlife than those without perinatal depression (38.1%; ARR 1.14, 95% CI 1.00, 1.30).”

    Humansadjusted for age, race/ethnicity, education, parity, BMI, and smoking status12-14 years after index birthfemalesn = 1,479

    Association of perinatal depression with vasomotor symptoms during midlife: A prospective community-based cohort study

    Maturitas

More on Perinatal depression

Cutaneous vascular conductance

upin humans1

1 study
  1. Vasomotor symptoms are associated with cutaneous vascular conductance in humans during 42 °C local heating (7.2 [1.7, 23.5]%).

    “During the 42 °C heating plateau, females with VMS exhibited greater %CVCmax than those without VMS when responses were pooled across regions (7.2 [1.7, 23.5]%; P = 0.013)”

    Humansduring 42 °C local heatingskinfemalesn = 18

    Postmenopausal vasomotor symptoms are associated with heightened cutaneous vasodilation despite preserved nitric oxide-mediated endothelial function

    Menopause (New York, N.Y.)

More on Cutaneous vascular conductance

Epigenetic age

upin humans1

1 study
  1. Vasomotor symptoms are associated with epigenetic age in humans (Severe vasomotor symptoms).

    “severe vasomotor symptoms have been linked to higher epigenetic age”

    ReviewSevere vasomotor symptomsfemales

    Biological markers of aging across the menopause transition: current evidence

    Menopause (New York, N.Y.)

More on Epigenetic age

Frequent mood changes

upin humans1

1 study
  1. Vasomotor symptoms are associated with frequent mood changes in humans (~50%-60% increased odds).

    “VMS and frequent mood changes were associated with ~50%-60% increased odds of the other”

    Humansn = 2,066

    Associations between vasomotor symptoms, sleep disturbances, and frequent mood changes individually and within symptom groups across the menopausal transition and early postmenopause: observations from the Study of Women's Health Across the Nation

    Menopause (New York, N.Y.)

Sleep disturbance

upin humans1

1 study
  1. Vasomotor symptoms are associated with sleep disturbance in humans (double the odds).

    “VMS and sleep disturbances were each associated with double the odds of the other”

    Humansn = 2,066

    Associations between vasomotor symptoms, sleep disturbances, and frequent mood changes individually and within symptom groups across the menopausal transition and early postmenopause: observations from the Study of Women's Health Across the Nation

    Menopause (New York, N.Y.)

More on Sleep disturbance

Worsening depressive symptoms

upin humans1OR 2.95

1 study
  1. Vasomotor symptoms are associated with worsening depressive symptoms in humans (Korean women during menopausal transition) (OR 2.95, 95% CI 1.30 to 6.70).

    “moderate-to-severe vasomotor symptoms (OR 2.95, 95% CI 1.30 to 6.70) were significantly associated with the worsening trajectory.”

    HumansKorean women during menopausal transitionfemales

    Longitudinal patterns and group heterogeneity of depressive symptoms during menopausal transition in middle-aged Korean women

    Epidemiology and psychiatric sciences

More on Worsening depressive symptoms

HDL

downin humans1

1 study
  1. HDL is associated with vasomotor symptoms in humans (before GnRH agonist-induced estradiol suppression) (median 53 vs 70 mg/dl).

    “significantly lower median HDL (53 mg/dl [47, 59] vs. 70 mg/dl [62, 73], p = 0.001)”

    Human trialbefore GnRH agonist-induced estradiol suppressionfemales

    MON-200 An Unfavorable Cardiovascular Profile Associates With The Development Of Vasomotor Symptoms In Premenopausal Women Undergoing Experimentally Induced Menopause

    ENDO 2025 abstract

More on HDL

Trunk/limb fat mass ratio

upin humans1

1 study
  1. Trunk/limb fat mass ratio is associated with vasomotor symptoms in humans (before GnRH agonist-induced estradiol suppression) (median 0.8 [0.7, 0.9] vs 0.7 [0.6, 0.7]).

    “Women who developed VMS, compared to women who did not, had significantly higher median pre-estradiol suppression trunk/limb fat mass ratios (0.8 [0.7, 0.9] vs. 0.7 [0.6, 0.7], p = 0.01)”

    Human trialbefore GnRH agonist-induced estradiol suppressionfemales

    MON-200 An Unfavorable Cardiovascular Profile Associates With The Development Of Vasomotor Symptoms In Premenopausal Women Undergoing Experimentally Induced Menopause

    ENDO 2025 abstract

More on Trunk/limb fat mass ratio

All 28

Trial sponsors

Funding

14 grants since 2018

National Institute on Aging$8.4MNational Heart, Lung, and Blood Institute$2.4MMassachusetts General Hospital$595K

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 21Jan 2026: 17Feb 2026: 28Mar 2026: 28Apr 2026: 38May 2026: 28Jun 2026: 50Jul 2026: 27Aug 2026: 36Sep 2026: 42Oct 2026: 39Nov 2026: 19373 papers in 12 months

See all 629 papers on vasomotor symptoms